{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:21:37Z","timestamp":1772083297676,"version":"3.50.1"},"reference-count":99,"publisher":"Hindawi Limited","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Depress Anxiety"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1002\/da.22433","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T17:13:20Z","timestamp":1444065200000},"page":"944-957","source":"Crossref","is-referenced-by-count":19,"title":["INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS"],"prefix":"10.1155","volume":"32","author":[{"given":"Bret R","family":"Rutherford","sequence":"first","affiliation":[{"name":"Columbia University College of Physicians and Surgeons; New York State Psychiatric Institute; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika S.","family":"Bailey","sequence":"additional","affiliation":[{"name":"New York State Psychiatric Institute; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin R.","family":"Schneier","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons; New York State Psychiatric Institute; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Pott","sequence":"additional","affiliation":[{"name":"New York State Psychiatric Institute; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Brown","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons; New York State Psychiatric Institute; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Roose","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons; New York State Psychiatric Institute; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2015,10,5]]},"reference":[{"key":"10.1002\/da.22433-BIB0001|da22433-cit-0001","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing","volume":"287","author":"Walsh","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1002\/da.22433-BIB0002|da22433-cit-0002","first-page":"1409","article-title":"Placebo response in antipsychotic clinical trials: a meta-analysis","volume":"71","author":"Rutherford","year":"2014","journal-title":"J Am Med Assoc Psychiatry"},{"key":"10.1002\/da.22433-BIB0003|da22433-cit-0003","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach","volume":"72","author":"Fava","year":"2003","journal-title":"Psychother Psychosom"},{"key":"10.1002\/da.22433-BIB0004|da22433-cit-0004","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1192\/bjp.178.3.192","article-title":"Placebo response in depression: bane of research, boon to therapy","volume":"178","author":"Andrews","year":"2001","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.22433-BIB0005|da22433-cit-0005","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"A model of placebo effects in antidepressant clinical trials","volume":"170","author":"Rutherford","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0006|da22433-cit-0006","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1176\/appi.ajp.159.5.728","article-title":"The functional neuroanatomy of the placebo effect","volume":"159","author":"Mayberg","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"Suppl 11","key":"10.1002\/da.22433-BIB0007|da22433-cit-0007","first-page":"30","article-title":"Placebo response in generalized anxiety: its effect on the outcome of clinical trials","volume":"58","author":"Schweizer","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0008|da22433-cit-0008","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.4088\/JCP.v67n1111","article-title":"Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of Escitalopram","volume":"67","author":"Stein","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0009|da22433-cit-0009","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/106002809603000917","article-title":"Placebo response in anxiety disorders","volume":"30","author":"Piercy","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1002\/da.22433-BIB0010|da22433-cit-0010","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1017\/S0033291704003873","article-title":"Magnitude of placebo response and drug-placebo differences across psychiatric disorders","volume":"35","author":"Khan","year":"2005","journal-title":"Psychol Med"},{"key":"10.1002\/da.22433-BIB0011|da22433-cit-0011","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jpsychires.2009.04.001","article-title":"Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial","volume":"43","author":"Feltner","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1002\/da.22433-BIB0012|da22433-cit-0012","first-page":"31","article-title":"Growing placebo response rate: the problem in recent therapeutic trials?","volume":"33","author":"Uhlenhuth","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"10.1002\/da.22433-BIB0013|da22433-cit-0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/cap.2009.0047","article-title":"Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders","volume":"20","author":"Cohen","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0014|da22433-cit-0014","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000209348","article-title":"Does study design affect outcome? The effects of placebo control and treatment duration in antidepressant trials","volume":"78","author":"Rutherford","year":"2009","journal-title":"Psychother Psychosom"},{"key":"10.1002\/da.22433-BIB0015|da22433-cit-0015","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jaac.2011.04.004","article-title":"Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact","volume":"50","author":"Rutherford","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.22433-BIB0016|da22433-cit-0016","volume-title":"Hierarchical Linear Models","author":"Bryk","year":"1992"},{"key":"10.1002\/da.22433-BIB0017|da22433-cit-0017","doi-asserted-by":"crossref","DOI":"10.4324\/9781410604118","volume-title":"Multilevel Analysis: Techniques and Applications","author":"Hox","year":"2002"},{"key":"10.1002\/da.22433-BIB0018|da22433-cit-0018","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1037\/1082-989X.3.3.339","article-title":"Using odds ratios as effect sizes for meta-analysis of dichotomous data: a primer on methods and issues","volume":"3","author":"Haddock","year":"1998","journal-title":"Psychol Methods"},{"key":"10.1002\/da.22433-BIB0019|da22433-cit-0019","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jaac.2011.04.004","article-title":"Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact","volume":"50","author":"Rutherford","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.22433-BIB0020|da22433-cit-0020","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jagp.2013.09.003","article-title":"Clinic visits in late life depression trials: effects on signal detection and therapeutic outcome","volume":"22","author":"Rutherford","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1002\/da.22433-BIB0021|da22433-cit-0021","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1002\/da.22433-BIB0022|da22433-cit-0022","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/oxfordjournals.aje.a009981","article-title":"Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis","volume":"150","author":"Takkouche","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1002\/da.22433-BIB0023|da22433-cit-0023","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0447.1999.tb10845.x","article-title":"Paroxetine in social anxiety disorder: a randomized placebo-controlled study","volume":"100","author":"Allgulander","year":"1999","journal-title":"Acta Psychiatr Scand"},{"key":"10.1002\/da.22433-BIB0024|da22433-cit-0024","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.161.9.1642","article-title":"Efficacy of sertraline in a 12-week trial for generalized anxiety disorder","volume":"161","author":"Allgulander","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0025|da22433-cit-0025","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/030079907X182202","article-title":"Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials","volume":"23","author":"Allgulander","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1002\/da.22433-BIB0026|da22433-cit-0026","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.602","article-title":"Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine","volume":"19","author":"Allgulander","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0027|da22433-cit-0027","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S1461145706006602","article-title":"Flovoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study","volume":"10","author":"Asakura","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1002\/da.22433-BIB0028|da22433-cit-0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients","volume":"103","author":"Asnis","year":"2001","journal-title":"Psychiatry Res"},{"key":"10.1002\/da.22433-BIB0029|da22433-cit-0029","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","article-title":"Paroxetine in social phobia\/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine study group","volume":"175","author":"Baldwin","year":"1999","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.22433-BIB0030|da22433-cit-0030","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","article-title":"Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study","volume":"189","author":"Baldwin","year":"2006","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.22433-BIB0031|da22433-cit-0031","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4088\/JCP.v66n0113","article-title":"Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline","volume":"66","author":"Ball","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0032|da22433-cit-0032","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1176\/ajp.155.1.36","article-title":"Double-blind, fixed dose, placebo-controlled study of paroxetine in the treatment of panic disorder","volume":"155","author":"Ballenger","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0033|da22433-cit-0033","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4088\/JCP.v65n0317","article-title":"Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison","volume":"65","author":"Bandelow","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0034|da22433-cit-0034","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10401230590932326","article-title":"A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder","volume":"17","author":"Bielski","year":"2005","journal-title":"Ann Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0035|da22433-cit-0035","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2012.07.012","article-title":"Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial","volume":"22","author":"Bidzan","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1002\/da.22433-BIB0036|da22433-cit-0036","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004850-198801000-00005","article-title":"Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline","volume":"3","author":"Den Boer","year":"1988","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0037|da22433-cit-0037","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/da.20355","article-title":"Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder","volume":"25","author":"Bose","year":"2008","journal-title":"Depress Anxiety"},{"key":"10.1002\/da.22433-BIB0038|da22433-cit-0038","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1192\/bjp.187.4.352","article-title":"Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study","volume":"187","author":"Bradwejn","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.22433-BIB0039|da22433-cit-0039","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4088\/JCP.v67n0603","article-title":"Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"67","author":"Brawman-Mintzer","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0040|da22433-cit-0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0447.1999.tb05384.x","article-title":"Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group","volume":"99","author":"Caillard","year":"1999","journal-title":"Acta Psychiatr Scand"},{"key":"10.1002\/da.22433-BIB0041|da22433-cit-0041","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study","volume":"19","author":"Davidson","year":"2004","journal-title":"Depress Anxiety"},{"key":"10.1002\/da.22433-BIB0042|da22433-cit-0042","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/01.jcp.0000106222.36344.96","article-title":"Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder","volume":"24","author":"Davidson","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0043|da22433-cit-0043","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0447.1986.tb02666.x","article-title":"Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo","volume":"73","author":"Evans","year":"1986","journal-title":"Acta Psychiatr Scand"},{"key":"10.1002\/da.22433-BIB0044|da22433-cit-0044","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.283.23.3082","article-title":"Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial","volume":"283","author":"Gelenberg","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1002\/da.22433-BIB0045|da22433-cit-0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/da.22365","article-title":"A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder","volume":"32","author":"Gommoll","year":"2015","journal-title":"Depress Anxiety"},{"key":"10.1002\/da.22433-BIB0046|da22433-cit-0046","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.186.3.222","article-title":"Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study","volume":"186","author":"Kasper","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.22433-BIB0047|da22433-cit-0047","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1440-1819.2006.01512.x","article-title":"Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder","volume":"60","author":"Kim","year":"2006","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1002\/da.22433-BIB0048|da22433-cit-0048","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","article-title":"Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study","volume":"22","author":"Kobak","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0049|da22433-cit-0049","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s002130050731","article-title":"A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder","volume":"139","author":"Lader","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/da.22433-BIB0050|da22433-cit-0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","article-title":"Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study","volume":"19","author":"Lader","year":"2004","journal-title":"Depress Anxiety"},{"key":"10.1002\/da.22433-BIB0051|da22433-cit-0051","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0447.1997.tb00388.x","article-title":"A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatr Scand"},{"key":"10.1002\/da.22433-BIB0052|da22433-cit-0052","first-page":"24","article-title":"Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial","volume":"25","author":"Leinonen","year":"2000","journal-title":"J Psychiatry Neurosci"},{"key":"10.1002\/da.22433-BIB0053|da22433-cit-0053","first-page":"772","article-title":"A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care","volume":"53","author":"Lenox-Smith","year":"2003","journal-title":"Br J Gen Pract"},{"key":"10.1002\/da.22433-BIB0054|da22433-cit-0054","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4088\/JCP.v65n0213","article-title":"Controlled-release paroxetine in the treatment of patients with social anxiety disorder","volume":"65","author":"Lepola","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0055|da22433-cit-0055","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","article-title":"Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study","volume":"64","author":"Liebowitz","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0056|da22433-cit-0056","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archpsyc.62.2.190","article-title":"Venlafaxine extended release vs. placebo and paroxetine in social anxiety disorder","volume":"62","author":"Liebowitz","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.22433-BIB0057|da22433-cit-0057","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.v66n0213","article-title":"SAD study group. A randomized controlled trial of venlafaxine extended release in generalized anxiety disorder","volume":"66","author":"Liebowitz","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0058|da22433-cit-0058","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","article-title":"Phenelzine vs. atenolol in social phobia. A placebo-controlled comparison","volume":"49","author":"Liebowitz","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.22433-BIB0059|da22433-cit-0059","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/bjp.173.1.54","article-title":"Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation","volume":"173","author":"Londborg","year":"1998","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.22433-BIB0060|da22433-cit-0060","first-page":"183","article-title":"Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder","volume":"29","author":"Lydiard","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"10.1002\/da.22433-BIB0061|da22433-cit-0061","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1176\/ajp.152.5.673","article-title":"Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships","volume":"152","author":"Mavissakalian","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0062|da22433-cit-0062","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1192\/bjp.179.6.514","article-title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial","volume":"179","author":"Michelson","year":"2001","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.22433-BIB0063|da22433-cit-0063","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1176\/ajp.155.11.1570","article-title":"Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group","volume":"155","author":"Michelson","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0064|da22433-cit-0064","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00004714-199208000-00007","article-title":"Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial","volume":"12","author":"Modigh","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0065|da22433-cit-0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q","article-title":"Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder","volume":"2","author":"Nair","year":"1996","journal-title":"Anxiety"},{"key":"10.1002\/da.22433-BIB0066|da22433-cit-0066","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00004850-200411000-00003","article-title":"Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study","volume":"19","author":"Nimatoudis","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0067|da22433-cit-0067","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1192\/bjp.167.3.374","article-title":"Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study","volume":"167","author":"Oehrberg","year":"1995","journal-title":"Br J Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/da.22433-BIB0068|da22433-cit-0068","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000284627","article-title":"Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone","volume":"22","author":"Pohl","year":"1989","journal-title":"Psychopathology"},{"key":"10.1002\/da.22433-BIB0069|da22433-cit-0069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20218","article-title":"A double-blind study of the efficacy of velafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder","volume":"24","author":"Pollack","year":"2007","journal-title":"Depress Anxiety"},{"key":"10.1002\/da.22433-BIB0070|da22433-cit-0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-007-0821-0","article-title":"A randomized controlled trial of velafaxine ER and paroxetine in the treatment of outpatients with panic disorder","volume":"194","author":"Pollack","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/da.22433-BIB0071|da22433-cit-0071","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","article-title":"Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial","volume":"55","author":"Pollack","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.22433-BIB0072|da22433-cit-0072","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4088\/JCP.v62n0508","article-title":"Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial","volume":"62","author":"Pollack","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0073|da22433-cit-0073","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1590\/S0100-879X2001001000010","article-title":"Mirtazapine versus fluoxetine in the treatment of panic disorder","volume":"34","author":"Ribeiro","year":"2001","journal-title":"Braz J Med Biol Res"},{"key":"10.1002\/da.22433-BIB0074|da22433-cit-0074","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.jcp.0000138764.31106.60","article-title":"A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder","volume":"24","author":"Rickels","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0075|da22433-cit-0075","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","article-title":"Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder","volume":"157","author":"Rickels","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0076|da22433-cit-0076","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.160.4.749","article-title":"Paroxetine treatment of generalized anxiety disorder: a double-blind placebo-controlled study","volume":"160","author":"Rickels","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0077|da22433-cit-0077","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States","volume":"22","author":"Rothschild","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1002\/da.22433-BIB0078|da22433-cit-0078","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/da.20271","article-title":"Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial","volume":"25","author":"Rynn","year":"2008","journal-title":"Depress Anxiety"},{"key":"10.1002\/da.22433-BIB0079|da22433-cit-0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1993.tb03405.x","article-title":"The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study","volume":"88","author":"Sheehan","year":"1993","journal-title":"Acta Psychiatr Scand"},{"key":"10.1002\/da.22433-BIB0080|da22433-cit-0080","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0081|da22433-cit-0081","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","article-title":"Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study","volume":"156","author":"Stein","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0082|da22433-cit-0082","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial","volume":"280","author":"Stein","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1002\/da.22433-BIB0083|da22433-cit-0083","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","article-title":"Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study","volume":"158","author":"Ameringen","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0084|da22433-cit-0084","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4088\/JCP.v68n0215","article-title":"Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial","volume":"68","author":"Ameringen","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0085|da22433-cit-0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0006-3223(97)00185-6","article-title":"Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls","volume":"42","author":"Vliet","year":"1997","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.22433-BIB0086|da22433-cit-0086","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1192\/bjp.170.6.549","article-title":"The effect of citalopram in panic disorder","volume":"170","author":"Wade","year":"1997","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.22433-BIB0087|da22433-cit-0087","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.jcp.0000104906.75206.8b","article-title":"A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder","volume":"24","author":"Westenberg","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0088|da22433-cit-0088","first-page":"3260","article-title":"Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China","volume":"124","author":"Wu","year":"2011","journal-title":"Chin Med J"},{"key":"10.1002\/da.22433-BIB0089|da22433-cit-0089","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.4088\/JCP.v68n0807","article-title":"A systematic review of placebo response in studies of bipolar mania","volume":"68","author":"Sysko","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22433-BIB0090|da22433-cit-0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1176\/appi.ajp.2008.08020247","article-title":"Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder","volume":"166","author":"Bridge","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0091|da22433-cit-0091","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1176\/appi.ajp.2013.12030315","article-title":"Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010","volume":"170","author":"Agid","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0092|da22433-cit-0092","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1176\/appi.ajp.2013.13081129","article-title":"Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle","volume":"170","author":"Leucht","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0093|da22433-cit-0093","first-page":"273","article-title":"Characteristics of placebo response during long-term treatment of panic disorder","volume":"26","author":"Dager","year":"1990","journal-title":"Psychopharmacol Bull"},{"key":"10.1002\/da.22433-BIB0094|da22433-cit-0094","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0447.1990.tb01401.x","article-title":"Drug treatment of panic disorder: early response to treatment as a predictor of final outcome","volume":"82","author":"Albus","year":"1990","journal-title":"Acta Psychiatr Scand"},{"key":"10.1002\/da.22433-BIB0095|da22433-cit-0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/npp.1994.63","article-title":"Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?","volume":"11","author":"Trivedi","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/da.22433-BIB0096|da22433-cit-0096","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/sim.2405","article-title":"Rater bias in a blinded randomized placebo-controlled psychiatry trial","volume":"25","author":"Marcus","year":"2006","journal-title":"Stat Med"},{"key":"10.1002\/da.22433-BIB0097|da22433-cit-0097","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0b013e31802eb4b7","article-title":"Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms?","volume":"27","author":"Kobak","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.22433-BIB0098|da22433-cit-0098","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1176\/appi.ajp.2011.11060864","article-title":"Antidepressant clinical trials and subject recruitment: just who are symptomatic volunteers?","volume":"168","author":"Brody","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22433-BIB0099|da22433-cit-0099","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1192\/bjp.bp.106.028555","article-title":"Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials","volume":"190","author":"Posternak","year":"2007","journal-title":"Br J Psychiatry"}],"container-title":["Depression and Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fda.22433","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/da.22433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T23:06:21Z","timestamp":1692054381000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/da.22433"}},"subtitle":["Research Article: Study Design and Treatment Response in Anxiety Disorders"],"short-title":[],"issued":{"date-parts":[[2015,10,5]]},"references-count":99,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"URL":"https:\/\/doi.org\/10.1002\/da.22433","archive":["Portico"],"relation":{},"ISSN":["1091-4269"],"issn-type":[{"value":"1091-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10,5]]}}}